Psoriasis comorbidities: complications and benefits of immunobiological treatment

Detalhes bibliográficos
Autor(a) principal: Carvalho,André Vicente Esteves de
Data de Publicação: 2016
Outros Autores: Romiti,Ricardo, Souza,Cacilda da Silva, Paschoal,Renato Soriani, Milman,Laura de Mattos, Meneghello,Luana Pizarro
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Anais brasileiros de dermatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781
Resumo: Abstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.
id SBD-1_2ef1a578cb16de491f2c0b0bb421158f
oai_identifier_str oai:scielo:S0365-05962016000600781
network_acronym_str SBD-1
network_name_str Anais brasileiros de dermatologia (Online)
repository_id_str
spelling Psoriasis comorbidities: complications and benefits of immunobiological treatmentComorbidityMetabolic Syndrome XPsoriasisTumor necrosis factor-alphaAbstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.Sociedade Brasileira de Dermatologia2016-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781Anais Brasileiros de Dermatologia v.91 n.6 2016reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20165080info:eu-repo/semantics/openAccessCarvalho,André Vicente Esteves deRomiti,RicardoSouza,Cacilda da SilvaPaschoal,Renato SorianiMilman,Laura de MattosMeneghello,Luana Pizarroeng2017-01-06T00:00:00Zoai:scielo:S0365-05962016000600781Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2017-01-06T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false
dc.title.none.fl_str_mv Psoriasis comorbidities: complications and benefits of immunobiological treatment
title Psoriasis comorbidities: complications and benefits of immunobiological treatment
spellingShingle Psoriasis comorbidities: complications and benefits of immunobiological treatment
Carvalho,André Vicente Esteves de
Comorbidity
Metabolic Syndrome X
Psoriasis
Tumor necrosis factor-alpha
title_short Psoriasis comorbidities: complications and benefits of immunobiological treatment
title_full Psoriasis comorbidities: complications and benefits of immunobiological treatment
title_fullStr Psoriasis comorbidities: complications and benefits of immunobiological treatment
title_full_unstemmed Psoriasis comorbidities: complications and benefits of immunobiological treatment
title_sort Psoriasis comorbidities: complications and benefits of immunobiological treatment
author Carvalho,André Vicente Esteves de
author_facet Carvalho,André Vicente Esteves de
Romiti,Ricardo
Souza,Cacilda da Silva
Paschoal,Renato Soriani
Milman,Laura de Mattos
Meneghello,Luana Pizarro
author_role author
author2 Romiti,Ricardo
Souza,Cacilda da Silva
Paschoal,Renato Soriani
Milman,Laura de Mattos
Meneghello,Luana Pizarro
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Carvalho,André Vicente Esteves de
Romiti,Ricardo
Souza,Cacilda da Silva
Paschoal,Renato Soriani
Milman,Laura de Mattos
Meneghello,Luana Pizarro
dc.subject.por.fl_str_mv Comorbidity
Metabolic Syndrome X
Psoriasis
Tumor necrosis factor-alpha
topic Comorbidity
Metabolic Syndrome X
Psoriasis
Tumor necrosis factor-alpha
description Abstract During the last decade, different studies have converged to evidence the high prevalence of comorbidities in subjects with psoriasis. Although a causal relation has not been fully elucidated, genetic relation, inflammatory pathways and/or common environmental factors appear to be underlying the development of psoriasis and the metabolic comorbidities. The concept of psoriasis as a systemic disease directed the attention of the scientific community in order to investigate the extent to which therapeutic interventions influence the onset and evolution of the most prevalent comorbidities in patients with psoriasis. This study presents scientific evidence of the influence of immunobiological treatments for psoriasis available in Brazil (infliximab, adalimumab, etanercept and ustekinumab) on the main comorbidities related to psoriasis. It highlights the importance of the inflammatory burden on the clinical outcome of patients, not only on disease activity, but also on the comorbidities. In this sense, systemic treatments, whether immunobiologicals or classic, can play a critical role to effectively control the inflammatory burden in psoriatic patients.
publishDate 2016
dc.date.none.fl_str_mv 2016-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962016000600781
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/abd1806-4841.20165080
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
dc.source.none.fl_str_mv Anais Brasileiros de Dermatologia v.91 n.6 2016
reponame:Anais brasileiros de dermatologia (Online)
instname:Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD
instname_str Sociedade Brasileira de Dermatologia (SBD)
instacron_str SBD
institution SBD
reponame_str Anais brasileiros de dermatologia (Online)
collection Anais brasileiros de dermatologia (Online)
repository.name.fl_str_mv Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)
repository.mail.fl_str_mv abd@sbd.org.br||revista@sbd.org.br
_version_ 1752126421419950080